Nanocrystal Delivery of Hydrophobic Anticancer Drugs

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R41EB013482-01A1
Agency Tracking Number: R41EB013482
Amount: $174,273.00
Phase: Phase I
Program: STTR
Awards Year: 2010
Solicitation Year: 2010
Solicitation Topic Code: NIBIB
Solicitation Number: PHS2010-2
Small Business Information
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL
500 Industrial Drive, Lawrenceburg, IN, 47025-2971
DUNS: 783437804
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 FRANK BEDUADDO
 (513) 755-3065
 FBEDUADDO@YAHOO.COM
Business Contact
 FRANK ADDO
Phone: (919) 966-3411
Email: resadminosr@unc.edu
Research Institution
 University Of North Carolina Chapel Hill
 Office Of Sponsored Research
CHAPEL HILL, NC, 27599-
 () -
 Nonprofit college or university
Abstract
DESCRIPTION (provided by applicant): Nanosystems have been extensively investigated for drug delivery; however, there is a challenge in transferring nanotechnology from research laboratories into pharmaceutical industry. The scientific basis for this proposal originated from our three-phase nanoparticle engineering (3PNE) method recently developed which includes phase 1, amorphous precipitate; phase 2, hydrated amorphous aggregate; and phase 3, stabilized nanocrystals (NCs). The 3PNE has been applied to the development of nanocrystals for the effective delivery of the anticancer drug, Paclitaxel (PTX). This nanocrystal is unique in its simplicity, low toxicity and its high drug loading ratio. The goal of this application is to further explore this novel nanotechnology and its feasibility for commercialization for intravenous PTX delivery. To achieve this goal, the following aims are proposed. Aim 1: Develop a technology to pave the way for large scale production of PTX nanocrystals. Aim 2: Characterize the PTX nanocrystals for their pharmaceutical kinetics, bio-distribution and acute toxicity in animals. Aim 3: Establish targeted PTX nanocrystals to further increase the anti-tumor efficiency. We believe that the success of this project will accelerate the commercialization of this nanotechnology for cancer therapy. PUBLIC HEALTH RELEVANCE: Paclitaxel nanocrystals developed using the novel three-phase nanoparticle engineering (3PNE) technology have significant potential for commercialization due to their simplicity, low toxicity, and cost effectiveness. The technology lowers drug dosing and improves efficacy.

* information listed above is at the time of submission.

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government